• Robert Carpenter, Chairman, Hydra Biosciences
  Director, Genzyme Corporation, Executive Chairman of the Board, Peptimmune, President, Boston Medical Investors
• Russell Herndon, President and Chief Executive Officer
• Michael Bigham, Director, Abingworth Limited
• Darren Carroll, Executive Director of New Ventures, Eli Lilly and Company
• Alan L. Crane, President and Chief Executive Officer, Tempo Pharmaceuticals
• Jean George, General Partner, Advanced Technology Ventures

Robert Carpenter

Bob Carpenter is a leader and pioneer in the healthcare and biotechnology industries. He is currently a director of Genzyme Corporation, Executive Chairman of Peptimmune, Inc., and president of Boston Medical Investors, Inc. Bob was a founder and chairman of GelTex Pharmaceuticals, which merged with Genzyme in 2000, and a founder, president and CEO of VacTex, which was acquired by Aquila Biopharmaceuticals in 1998. He was also chairman of the board, president and CEO of Integrated Genetics, Inc., a biotechnology company that merged with Genzyme Corporation in 1989. Following that merger and until 1991, Bob was EVP, CEO and chairman of its subsidiary IG Laboratories, Inc. Bob is a graduate of West Point. He earned his master's in computer science from Stanford and his MBA from Harvard Business School.

Russell Herndon

Russell Herndon comes to Hydra with over 25 years of experience in the healthcare and biotechnology industries, with a proven track record in building successful business infrastructures, pioneering innovative corporate and regulatory processes and advancing products through development. His industry experience includes senior management positions at Genzyme Corporation and Antigenics Inc., where he led some of the companies' most strategic and important initiatives. At Antigenics, Russ served as Chief Operating Officer and President. From November 2003 through December 2005 he held the position of President of Commercial Operations. He was with Genzyme Corporation from 1989 through 2000 holding various management positions, including President of Genzyme Tissue Repair, Senior Vice President of Genzyme Tissue Repair and Vice President of regulatory affairs for Genzyme Corporation. Prior to joining Genzyme, Russ gained extensive experience in the area of quality systems, including management positions at Patton Company, Paco Research & Development and Alcon Laboratories Incorporated. Russ received a bachelor's degree in biology from Barton College and is a graduate of the Management Development Program at Harvard Business School.

Michael Bigham

Michael Bigham is a Director of Abingworth Limited and manages the Waltham office. He was Vice Chairman of Corixa Corporation from December 2000 to March 2004, and was President and Chief Executive of Coulter Pharmaceuticals from July 1996 until it merged into Corixa in December 2000. Previously, he was an early employee at Gilead Sciences where he spent eight years serving in various capacities, including Executive Vice President of Operations and CFO. Before joining Gilead, Michael was a partner at Hambrecht & Quist where he became Co-Head of Healthcare Investment Banking. He has a BS Degree with distinction from the University of Virginia and qualified as a CPA before completing his MBA at the Stanford University Graduate School of Business.

Darren Carroll

Darren J. Carroll is Executive Director of New Ventures for Eli Lilly and Company, a leading innovation driven pharmaceutical corporation. The New Ventures group is responsible for all venture capital investments made by Lilly, as well as development and incubation of new business models. Prior to assuming his role at New Ventures, Darren was the founding chief executive officer of InnoCentive, Inc., the first e-business venture created by Lilly. Among other positions at Lilly and Company, he was the U.S. attorney for Prozacª, responsible for advising the company on all legal issues pertaining to the marketing and related clinical development of antidepressants in the Lilly pipeline. Darren has also served as senior vice president of RealMed, which created the first U.S. real-time health claims adjudication system. Earlier in his career, he practiced law with a large private law firm in New York and negotiated technology transactions for General Electric Company. His education includes a J.D. degree from the Syracuse University College of Law. At Syracuse, where he was a member of the Law Review and Order of the Coif. He also holds a bachelor's from Syracuse University (Phi Beta Kappa) and a masters of public administration degree from the Maxwell School of Syracuse, where he is a member of the Board of Advisors. Darren is also a member of the Board of Directors for other Lilly Ventures portfolio companies including GlobeImmune and Nanostream.

Alan L. Crane

Mr. Crane is currently President and CEO of Tempo Pharmaceuticals, Inc. He has also been a venture partner at Polaris Ventures since April of 2002. From 2002 until 2006, Mr. Crane was President and CEO of Momenta Pharmaceuticals. He joined Momenta as the fifth employee and built the company into a public company, creating an advanced and diversified pipeline, entering into two strategic collaborations with the Sandoz division of Novartis, and raising $275M. Prior to this, Mr. Crane was senior vice president of global corporate development at Millennium Pharmaceuticals, where he was responsible for leading Millennium's strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding and acquiring 19 development stage products. Prior to Millennium, Mr. Crane was a marketing executive at Dupont-Merck and a consultant with the Boston Consulting Group and Arthur D. Little.  

Alan received his M.B.A. in 1992 and his B.A. summa cum laude and M.A. in 1986, all from Harvard University. Mr. Crane also attended Harvard Medical School from 1986 to 1988 before pursuing a business career.

Jean George

Jean brings more than 20 years of biopharmaceutical industry experience to ATV, including 10 years at Genzyme Corporation. At Genzyme, she held a variety of operational roles in marketing, product development and business development, including Vice President of Global Sales and Marketing. She also worked as Vice President and Founder of Genzyme's Tissue Repair Division, where she was responsible for identifying new product opportunities and potential acquisition candidates. In 1998 Jean joined the venture capital community when she was appointed to lead BancBoston Ventures' life sciences investments. At BancBoston Ventures Jean led investments in Neurometrix (NASDAQ: NURU), Microbia, NuGenesis Technologies (acquired by Waters), and Syntonix Pharmaceuticals Biogen-Idec. In addition to her extensive operating and investment background, Jean also spent six years working in chemistry and bioresearch. Jean holds an M.B.A. from Simmons College Graduate School of Management and a B.S. from the University of Maine.